India-based Cipla has announced a collaboration with the U.K. government to invest up to $170 million in its U.K. subsidiary over the next few years.

The investment will fund the launch of a range of drugs in the areas of respiratory, oncology and antiretroviral medicines, as well as R&D, clinical trials and expansion internationally and in the U.K.

“Cipla believes that, by providing high-quality affordable medicines for patients, it can contribute cost-effective solutions for the NHS,” said Rajesh Garg, global chief financial officer and board member of Cipla. “We were impressed with the pro-active support and engagement that the U.K. government and its various ministries showed in attracting Cipla to choose the U.K. as a key hub in our global footprint.”